Skip to main content

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) (“Supernus“, and the “Company”), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act“), with respect to Supernus’ proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ: SAGE) (“Sage“), expired at 11:59 p.m. Eastern Time on July 25, 2025. On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger (the “Merger Agreement“), by and among Supernus, Sage and Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus (“Purchaser“). On June 25, 2025 and June 30, 2025, Supernus and Sage, respectively,...

Continue reading

Savi Financial Corporation and SaviBank Provide Update to Shareholders Regarding Closing of Acquisition

MOUNT VERNON, Wash., July 28, 2025 (GLOBE NEWSWIRE) — Savi Financial Corporation, Inc. (OTC Pink: SVVB) (“Savi Financial” or the “Company”) and its wholly owned subsidiary, SaviBank, today announced that all parties have received final regulatory approval to complete the acquisition of SaviBank’s operating assets and the assumption of SaviBank’s deposits by Tacoma-based Harborstone Credit Union. The acquisition was announced on March 21, 2024, upon the parties’ entry into a Purchase and Assumption Agreement on that date. “We are delighted to have received our final approvals to allow the transaction to proceed to closing,” stated Michal D. Cann, Chairman and President of Savi Financial Corporation. “Although regulatory approval has taken longer than we had hoped, we are enthusiastic in that the approvals are not subject to any...

Continue reading

AMG and Montefiore Investment Announce Partnership

AMG to invest in Montefiore, a leading European private equity firm with €5 billion in AUM, focused on the services sector  Montefiore has a 20-year track record of consistently delivering top-tier returns by leveraging its differentiated strategy, sector expertise, unique sourcing capability, and value-creation skills   Montefiore’s management will retain a substantial majority of the firm’s equity and continue to lead Montefiore as an independent firm, in line with AMG’s partnership approach   Partnership further diversifies AMG’s business and expands its participation in global private markets  WEST PALM BEACH, Fla. and PARIS, July 28, 2025 (GLOBE NEWSWIRE) — AMG, a strategic partner to leading independent investment management firms globally, today announced that it has entered into a definitive agreement to acquire a minority...

Continue reading

Torex Gold to Acquire Prime Mining

Combination creates a leading diversified Americas-focused precious metals company (All amounts expressed in Canadian dollars unless otherwise stated) TORONTO, July 28, 2025 (GLOBE NEWSWIRE) — Torex Gold Resources Inc. (“Torex”, the “Company”) (TSX:TXG) (OTCQX:TORXF) and Prime Mining Corp. (“Prime Mining”) (TSX: PRYM) (OTCQX: PRMNF) (Frankfurt: O4V3) are pleased to announce that they have entered into a definitive agreement (the “Arrangement Agreement”) whereby Torex will acquire all of the issued and outstanding common shares of Prime Mining (the “Prime Mining Shares”) pursuant to a plan of arrangement (the “Transaction”). The Transaction will result in Torex owning a 100% interest in Prime Mining’s multi-million ounce Los Reyes gold-silver project (“Los Reyes” or the “Los Reyes Project”). The Los Reyes Project is located in Mexico,...

Continue reading

McEwen Inc. and Canadian Gold Corp. Announce Letter of Intent

TORONTO and FLIN FLON, Manitoba, July 28, 2025 (GLOBE NEWSWIRE) — McEwen Inc. (“McEwen”) (NYSE: MUX) (TSX:MUX) and Canadian Gold Corp. (“Canadian Gold”) (TSX-V:CGC) are pleased to announce that they have entered into a binding letter of intent (the “LOI“) on July 27, 2025 in respect of a proposed transaction (the “Proposed Transaction“), whereby McEwen would acquire all of the issued and outstanding securities of Canadian Gold by way of plan of arrangement. If the Proposed Transaction is completed, Canadian Gold would become a wholly-owned subsidiary of McEwen. Canadian Gold’s principal asset is its 100% interest in the Tartan Mine, which is located in Manitoba, Canada (the “Tartan Mine“). The Tartan Mine is a high-grade former producing mine with existing infrastructure and high exploration...

Continue reading

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...

Continue reading

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) —  Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...

Continue reading

Apple iSports Signs Definitive Agreement to Acquire LBC Enterprises Pty Ltd

IRVINE, Calif., July 25, 2025 (GLOBE NEWSWIRE) — Apple iSports (OTC-QB: AAPI) (“Company” or “Apple iSports” or “AiS”), a gaming, entertainment, and technology services company, is pleased to announce it has signed a Definitive Agreement with LBC Enterprises Pty Ltd (“LBC” or “Lucky Bet”), an online gaming, wagering, and payment systems company. Key HighlightsLBC Enterprises Pty Ltd, a Queensland, Australia corporation, will sell all its shares to Apple iSports. The Board of Directors of both LBC and Apple iSports have unanimously approved the proposed transaction, which is expected to close in the third quarter of 2025, subject to any regulatory approvals and the satisfaction of closing conditions in the Definitive Agreement. LBC will continue to operate under its brand and will be led by Mr. Ian Parke, the CEO of LBC. Messrs....

Continue reading

Transom Capital and SigmaTron International Announce Expiration of Tender Offer

LOS ANGELES and ELK GROVE VILLAGE, Ill., July 25, 2025 (GLOBE NEWSWIRE) — Transom Capital Group, LLC (“Transom”) and SigmaTron International, Inc. (NASDAQ: SGMA) (“SigmaTron”), today announced that the tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.01 per share (“Shares”) of SigmaTron at a purchase price of $3.02 per Share, net to the stockholder in cash without interest and less any required tax withholding (the “Offer”), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on July 24, 2025 and was not extended (such date and time, the “Expiration Date”). Equiniti Trust Company, LLC, the depositary and paying agent for the Offer, has advised Transom that, as of the Expiration Date, 4,401,189 Shares were validly tendered and not validly withdrawn in the Offer, representing...

Continue reading

Form 8.3 – [MARLOWE PLC – 24 07 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree MARLOWE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.